肺炎支原体肺炎T细胞亚群免疫球蛋白水平变化的研究

Serum levels of T cell subgroups and immunoglobulins in children with Mycoplasma pneumoniae pneumonia

摘要:

目的：为了正确认识肺炎支原体肺炎(MPP)患儿免疫状态,该研究检测了MPP患儿外周血T细胞亚群、免疫球蛋白的变化,旨在探讨MPP患儿免疫功能的特点。方法：采用流式细胞仪技术(FCM)检测了32例支原体肺炎患儿外周血T细胞亚群及免疫球蛋白,并与28例正常儿童进行比较。结果：MPP患儿急性期外周血CD3,CD4,CD8,CD4/CD8分别为57.30±6.21个/μL,32.70±6.52个/μL,24.9±2.41个/μL,1.31±0.33,恢复期外周血CD3,CD4,CD8,CD4/CD8分别为58.20±6.10个/μL,34.92±5.93个/μL,25.87±4.72个/μL,1.39±0.42,CD4,CD4/CD8较对照组低,P<0.05。MPP患儿外周血急性期IgG,IgA,IgM分别为9.93±2.67g/L,1.63±0.69g/L,1.73±0.83g/L,恢复期分别为11.45±2.97g/L,1.94±0.84g/L,2.17±1.23g/L,IgG,IgM较对照组高,P<0.01。IgA与对照组比较无明显差异。结论：肺炎支原体肺炎时患儿存在细胞免疫和体液免疫失调,该研究为临床应用免疫调节剂提供了理论依据。

Abstract:

OBJECTIVE: This study examined the serum levels of T cell subgroups and immunoglobulins in children with Mycoplasma pneumoniae pneumonia (MPP) in order to investigate the patients' immune function. METHODS: Flow cytometry (FCM) was used to determine the serum levels of T cell subgroups and immunoglobulins in 32 children with MPP at acute and recovery stages. Serum samples from 28 healthy children served as controls. RESULTS: The CD4 content (32.70±6.52/μL) and the ratio of CD4/CD8 (1.31±0.33) at acute stage in children with MPP were significantly lower that those in controls (40.15±4.49 /μL and 1.79±0.52, respectively) (P<0.01). Till to the recovery stage, the CD4 content (34.92±5.93/μL) and the ratio of CD4/CD8 (1.39±0.42) remained lower (P<0.01). There was no difference in the CD3 content between the MPP patients and controls at both the acute and recovery stages. The children with MPP showed higher serum concentrations of IgG (9.93±2.67 g/L) and IgM (1.73±0.83 g/L) at acute stage compared with the controls (8.01±2.47 g/L and 1.05±0.32 g/L respectively) (P<0.01). A significant difference for the serum concentrations of IgG and IgM was also observed at the recovery stage between MPP patients and controls. IgA content was not different between them. CONCLUSIONS: Immune function disturbance may exist in children with MPP. This study provides a basis for clinical application of immune regulators in the treatment of MPP.